Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL Schizophrenia Maintenance
NCT01435928Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma America. Started Sep 2011; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01435928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435928.